U.S. markets closed
  • S&P 500

    +31.63 (+0.77%)
  • Dow 30

    +297.03 (+0.89%)
  • Nasdaq

    +70.88 (+0.51%)
  • Russell 2000

    +0.88 (+0.04%)
  • Crude Oil

    -0.26 (-0.44%)
  • Gold

    -14.10 (-0.80%)
  • Silver

    -0.26 (-1.02%)

    -0.0016 (-0.13%)
  • 10-Yr Bond

    +0.0340 (+2.08%)

    -0.0028 (-0.20%)

    +0.3660 (+0.33%)

    -914.84 (-1.51%)
  • CMC Crypto 200

    +8.34 (+0.68%)
  • FTSE 100

    -26.47 (-0.38%)
  • Nikkei 225

    +59.08 (+0.20%)

Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CAR-T Therapy

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

AVA-101 designed to enhance efficacy and overcome safety challenges of current CAR-T immune-oncology therapeutics

AVA-101 represents a first-in-class transposon-based Chimeric Antigen Receptor (CAR) system targeting both CD19 and CD22 on tumor cells, enabling a flexible, combinational and cost-effective cancer immunotherapy

FREEHOLD, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (AVCO) (NASDAQ listed Avalon GloboCare AVCO), a leading global developer of innovative and transformative cell-based technologies and therapeutics, announced today that the Company and Arbele Limited (joint venture partner) have jointly filed provisional patent applications covering method and composition of matter claims for AVA-101, a novel multi-targeted, transposon-based Chimeric Antigen Receptor (CAR)-T cellular immunotherapy. These unique CAR vector constructs are non-virally engineered, possessing multiple therapeutic targets as well as unique “safety-switch" control mechanisms, designed to provide more effective therapy and overcome toxicities of current CAR-T therapy.

This set of patent applications primarily involves an innovative, versatile and inducible transposon-based vector system composed of humanized CD19 and CD22 dual and bispecific CARs with a safety switch targeted by Rituximab. Furthermore, the system enables a combination therapy with anti-immune check point inhibitors as well as other factors to support effector CAR-T cell survival for more efficacious, durable and safer cellular immunotherapy for treating patients with progressive hematologic malignancies.

“We are very excited to achieve this milestone after establishing our joint venture with Arbele Limited on January 3, 2019,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp. “This patent application, together with Avalon’s extensive hospital network for cellular therapy and our established GMP bio-production facility in China, should allow Avalon to accelerate the clinical development of better and safer CAR-T therapies and, as a result, further establish our leadership in the field of immuno-oncology and cell-based therapeutics,” added Dr. Jin.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020